NovelMed Therapeutics

Focus: NovelMed is a public biotechnology company headquartered in Cleveland, Ohio, specializing in monoclonal antibody therapeutics for nephrology, immunology, and rare diseases.

Nephrology Immunology Rare Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About NovelMed Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow NovelMed Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

9 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

NM8074

Healthy

PHASE_1

Clinical Trials (1)

NCT05642546First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers

Phase 1

Help build intelligence for NovelMed Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline of 9 active trials centered on a single lead asset (NM8074) spanning multiple rare disease indications, offering deep technical expertise in complement pathway biology and monoclonal antibody optimization
Rare disease focus in nephrology and immunology represents differentiated therapeutic areas with high unmet medical need and potential for accelerated regulatory pathways
Public company status provides access to capital markets and established infrastructure, reducing early-stage biotech risk while maintaining specialized focus

Watch Out For

Minimal hiring activity (only 1 open R&D role) signals limited near-term headcount expansion or potential resource constraints despite public status
Pipeline is entirely Phase 1-2 stage with zero Phase 3 programs; no near-term catalysts or revenue-generating approvals on horizon, extending cash burn timeline
Data gaps on revenue, employee count, founding date, and ticker symbol suggest either stealth operations or minimal public disclosure, raising transparency and stability concerns

Generated by Claude from NovelMed Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NM8074

C3 Glomerulopathy

PHASE_1_2

Clinical Trials (1)

NCT05647811Study of NM8074 in Adult C3 Glomerulopathy Patients

Phase 1/2

NM8074

IgA Nephropathy

PHASE_2

Clinical Trials (1)

NCT06454110Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)

Phase 2